Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1517534 | 0.89 | TSHR (0.37) | TSHRACACB | |
| SCHEMBL850358 | 0.81 | TGFBR1 (0.33) | — | |
| SCHEMBL2494021 | 0.76 | TSHR (0.44) | TSHRACACB | |
| SCHEMBL4245910 | 0.74 | TSHR (0.42) | TSHRACACB | |
| SCHEMBL307976 | 0.73 | TSHR (0.41) | TSHRACACB | |
| SCHEMBL515064 | 0.72 | TSHR (0.40) | TSHRACACB | |
| SCHEMBL1517529 | 0.71 | TSHR (0.39) | TSHRACACB | |
| SCHEMBL1517424 | 0.69 | ACACB (0.34) | TSHRACACB | |
| SCHEMBL16594934 | 0.69 | TSHR (0.44) | TSHRACACB | |
| SCHEMBL29264597 | 0.69 | TSHR (0.47) | TSHRACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12638614-B2 | Method for making silicone hydrogel contact lenses | ALCON INC. (CH) | 2026-05-26 | — | — | US | claimed |
| EP-4514596-B1 | METHOD FOR MAKING SILICONE HYDROGEL CONTACT LENSES | ALCON INC (CH) | 2026-03-04 | — | — | EP | claimed |
| EP-4514596-A1 | METHOD FOR MAKING SILICONE HYDROGEL CONTACT LENSES | Alcon Inc. (CH) | 2025-03-05 | — | — | EP | claimed |
| EP-4514597-A1 | METHOD FOR MAKING UV AND HEVL-ABSORBING OPHTHALMIC LENSES | Alcon Inc. (CH) | 2025-03-05 | — | — | EP | claimed |
| WO-2023209631-A1 | METHOD FOR MAKING UV AND HEVL-ABSORBING OPHTHALMIC LENSES | ALCON INC. (CH) | 2023-11-02 | — | — | WO | claimed |
| US-20230350100-A1 | METHOD FOR MAKING SILICONE HYDROGEL CONTACT LENSES | ALCON INC. (CH) | 2023-11-02 | — | — | US | claimed |
| WO-2023209630-A1 | METHOD FOR MAKING SILICONE HYDROGEL CONTACT LENSES | ALCON INC. (CH) | 2023-11-02 | — | — | WO | claimed |
| EP-3052534-B1 | METHOD FOR MAKING UV-ABSORBING OPHTHALMIC LENSES | NOVARTIS AG (CH) | 2019-05-01 | — | — | EP | claimed |
| EP-3052534-A1 | METHOD FOR MAKING UV-ABSORBING OPHTHALMIC LENSES | Novartis AG (CH) | 2016-08-10 | — | — | EP | claimed |
| US-9315669-B2 | Method for making UV-absorbing ophthalmic lenses | NOVARTIS AG (CH) | 2016-04-19 | — | — | US | claimed |
| WO-2015048035-A1 | METHOD FOR MAKING UV-ABSORBING OPHTHALMIC LENSES | NOVARTIS AG (CH) | 2015-04-02 | — | — | WO | claimed |
| US-8383744-B2 | Actinically-crosslinkable siloxane-containing copolymers | NOVARTIS AG (CH) | 2013-02-26 | — | — | US | claimed |
| US-20120172478-A1 | METHOD FOR MAKING SILICONE HYDROGEL CONTACT LENSES | ALCON INC. (CH) | 2012-07-05 | — | — | US | claimed |
| US-8163206-B2 | Method for making silicone hydrogel contact lenses | NOVARTIS AG (CH) | 2012-04-24 | — | — | US | claimed |
| EP-2432808-A1 | ACTINICALLY-CROSSLINKABLE SILOXANE-CONTAINING COPOLYMERS | Novartis AG (CH) | 2012-03-28 | — | — | EP | claimed |
| EP-2374031-A1 | METHOD FOR MAKING SILICONE HYDROGEL CONTACT LENSES | Novartis AG (CH) | 2011-10-12 | — | — | EP | claimed |
| WO-2010133680-A1 | ACTINICALLY-CROSSLINKABLE SILOXANE-CONTAINING COPOLYMERS | NOVARTIS AG (CH) | 2010-11-25 | — | — | WO | claimed |
| US-20100296049-A1 | ACTINICALLY-CROSSLINKABLE SILOXANE-CONTAINING COPOLYMERS | ALCON INC. (CH) | 2010-11-25 | — | — | US | claimed |
| US-20100258961-A1 | Method for making silicone hydrogel contact lenses | ALCON INC. (CH) | 2010-10-14 | — | — | US | claimed |
| WO-2010071691-A1 | METHOD FOR MAKING SILICONE HYDROGEL CONTACT LENSES | NOVARTIS AG (CH) | 2010-06-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100296049-A1 | ACTINICALLY-CROSSLINKABLE SILOXANE-CONTAINING COPOLYMERS | VCL, MACF1, CFL1 | TSHR 3589/4885ACACB 2586/4885 |
| US-12638614-B2 | Method for making silicone hydrogel contact lenses | SMCHD1, CRYAA, CRYZ | TSHR 1465/4885ACACB 1261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.